Advances in artificial intelligence and molecular imaging technology are rapidly transforming oncology diagnostics. Researchers have developed an AI-driven diagnostic tool at Dana-Farber Cancer Institute using DNA methylation and machine learning to subtype acute leukemia with greater accuracy. Similarly, a novel PET tracer targeting nectin-4 allows same-day imaging of aggressive triple-negative breast and urothelial cancers, potentially enabling faster clinical decisions. These innovations exemplify the fusion of AI and molecular tools to enhance cancer detection and patient stratification.